Harrow, Inc. (HROW) Stock Price & Analysis
Harrow, Inc. (HROW) rose 1.09% to USD 33.46 as of June 10, 2026 at 03:35 UTC, according to Nexqual real-time market data.
HROW last closed at USD 33.1; the session ranged USD 33.23–34.43 on volume of 875,503 shares. Market capitalization is $1.25B, with a 52-week range of USD 28.54–54.85 (NGM). Source: Nexqual, June 10, 2026 at 03:35 UTC.
Key Statistics (as of June 10, 2026 at 03:35 UTC)
| Price | USD 33.46 |
|---|---|
| Change | ▲ 1.09% (up) |
| Previous Close | USD 33.1 |
| Open | USD 33.6 |
| Day Range | USD 33.23 – 34.43 |
| 52-Week Range | USD 28.54 – 54.85 |
| Volume | 875,503 shares |
| Market Cap | $1.25B |
| Exchange | NGM |
Technical Analysis (HROW)
Nexqual's technical model rates HROW "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.33 (neutral) |
| vs SMA50 | Below (USD 36.13) |
| MACD | -0.78 (negative) |
Analyst Ratings (HROW)
Wall Street analysts rate HROW "Strong Buy" based on 8 analysts, with a mean price target of USD 67.75 (range USD 59–88), per Nexqual as of June 10, 2026 at 03:35 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 67.75 |
| High Target | USD 88 |
| Low Target | USD 59 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (HROW)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $70.96M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.74 vs est -0.33 ▼ miss |
| 2025-09-30 | USD 0.33 vs est 0.29 ▲ beat |
| 2025-06-30 | USD 0.24 vs est 0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financials & Fundamentals (HROW)
| Total Revenue | $268.68M |
|---|---|
| Revenue Growth (YoY) | -7.60% |
| Gross Margin | +74.11% |
| Operating Margin | -49.95% |
| Profit Margin | -5.57% |
| ROE | -35.43% |
| Debt / Equity | 1,060.52 |
| Current Ratio | 2.48 |
| Total Cash | $95.97M |
| Total Debt | $300.67M |
| Free Cash Flow | $-5.05M |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financial Health Score (HROW)
Nexqual rates Harrow, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:35 UTC.
| Growth | Strong — Revenue +36% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 74%, operating -50% |
| Balance Sheet | Weak — $96M cash vs $301M debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -35%, ROA 3.1% |
Ownership (HROW)
| Insider Ownership | +15.47% |
|---|---|
| Institutional Ownership | +58.86% |
| Shares Outstanding | 37.28M |
| Float | 28.28M |
| Short % of Float | +19.98% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Leadership (HROW)
Harrow, Inc. is led by Mark L. Baum (age 53), CEO, Chairman of the Board & Founder, per Nexqual as of June 10, 2026 at 03:35 UTC.
| CEO, Chairman of the Board & Founder | Mark L. Baum (age 53) |
|---|---|
| President, CFO & Corporate Secretary | Andrew R. Boll C.F.A., C.M.A. (age 43) |
| Chief Scientific Officer | Amir W. Shojaei Ph.D., Pharm.D. (age 57) |
| President & CEO of Harrow's ImprimisRx Division | Francis W. Mullery |
| Vice President of Investor Relations & Communications | Michael D. Biega |
Major Backers & Investors (HROW)
Notable institutional backers of Harrow, Inc. include Opaleye Management Inc., Private Capital Management, LLC, Luxor Capital Group, LP, according to Nexqual as of June 10, 2026 at 03:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 7.6% |
| Private Capital Management, LLC | 4.19% |
| Luxor Capital Group, LP | 3% |
| Marshall Wace LLP | 1.73% |
| Ikarian Capital, LLC | 1.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.54% |
| Vanguard Group | 7.86% |
| State Street | 2.75% |
| Geode Capital | 2.29% |
| Dimensional Fund Advisors | 1.55% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
From Harrow, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- As a potential FDA-approved successor, MELT-300 is a patented, sublingually delivered formulation of a fixed dose of midazolam (3mg) and ketamine (50mg) designed to provide rapid, predictable sedation without the need for intravenous administration.
- We do, however, believe that our drug candidates and drug products could have commercial appeal in international markets, and have engaged distributors and entered into out-licensing arrangements for certain of our products and proprietary formulations in certain non-U.S. markets, including Canada.
- Manufacturers, including us, are required to report average sales price information to the Centers for Medicare & Medicaid Services ("CMS") on a quarterly basis.
- As a condition of approval, the FDA or other regulatory authorities may require further studies, including Phase 4 post-marketing studies, to provide additional data.
Partnerships
- In addition, inventions relevant to us could be developed by a person not bound by an invention assignment agreement with us, in which case we may have no rights to use the applicable invention.   The following table lists some of our outstanding material patents in the U.S. covering certain branded products we own commercial rights to, general subject matter and latest expiry date.
- For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLPT | ClearPoint Neuro Inc. | USD 13.59 | ▲ 5.43% |
| ETON | Eton Pharmaceuticals, Inc. | USD 30.53 | ▲ 4.81% |
| LQDA | Liquidia Corporation | USD 64.01 | ▲ 3.49% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| TMDX | TransMedics Group, Inc. | USD 74.29 | ▲ 7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:35 UTC. This page is informational and not investment advice.